大洋生物(003017.SZ):“年產2.5萬噸碳酸鉀和1.5萬噸碳酸氫鉀項目”先期竣工通過環境保護驗收
格隆匯 1 月 19日丨大洋生物(003017.SZ)公佈,公司近日通過“年產2.5萬噸碳酸鉀和1.5萬噸碳酸氫鉀項目”先期竣工環境保護先行驗收。
通過此次項目環境保護先行驗收,標誌着公司碳酸鉀綜合產能由原來的6.5萬噸/年提高到7.7萬噸/年(含碳酸氫鉀摺合),為公司經營業績的增長提供了產能支撐。後續公司將不斷完善項目環保設施的運行維護,強化環境風險防控措施,不斷提高公司環保工作管理水平,保障項目充分發揮其產能優勢,為公司後續發展奠定堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.